Plain-English translation of NCT04655170 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether Revefenacin and Formoterol—two long-acting breathing medicines given once or twice daily—work better than the standard short-acting medicines (Albuterol and Ipratropium) given every 6 hours for people hospitalized with a sudden COPD flare-up. Researchers want to know if the new medication helps patients breathe easier, need fewer emergency doses, and recover faster during their hospital stay.
Currently, doctors treat hospitalized COPD flare-ups with short-acting medicines given frequently throughout the day. This trial explores whether longer-acting medicines—requiring fewer doses—might be safer, easier to use, and just as effective or better at relieving breathing difficulties.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the new breathing medicine schedule (once or twice daily) or the standard schedule (every 6 hours) while you are in the hospital for up to 7 days or until discharge. During your stay, doctors will measure how well you're breathing using a simple scale twice daily, track how much oxygen you need, monitor how many extra rescue doses you use, and check your blood work and chest X-ray on specific days (Days 1, 3, 7, or at discharge).
AI-generated summary from trial data · Jul 11, 2026 · Not medical advice
United States